Denali Therapeutics Inc. (DNLI) Social Stream
DENALI THERAPEUTICS INC (DNLI) Price Targets From Analysts
Use the tables below to see what analysts covering DENALI THERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-12 | 11 | $105 | $60 | $84.4 | $21.46 | 293.29% |
| 2021-11-17 | 11 | $105 | $60 | $84.3 | $21.46 | 292.82% |
| 2021-12-22 | 11 | $105 | $60 | $81.3 | $21.46 | 278.84% |
| 2022-01-13 | 10 | $105 | $60 | $80.5 | $21.46 | 275.12% |
| 2022-01-20 | 10 | $105 | $60 | $78.5 | $21.46 | 265.8% |
| 2022-02-10 | 10 | $105 | $60 | $76.1 | $21.46 | 254.61% |
| 2022-03-01 | 11 | $105 | $60 | $75.1 | $21.46 | 249.95% |
| 2022-05-06 | 11 | $105 | $41 | $73.2 | $21.46 | 241.1% |
| 2022-05-08 | 11 | $105 | $41 | $71.8 | $21.46 | 234.58% |
| 2022-05-13 | 10 | $105 | $41 | $70.333 | $21.46 | 227.74% |
| 2022-05-24 | 11 | $105 | $41 | $71.5 | $21.46 | 233.18% |
| 2022-08-16 | 12 | $105 | $39 | $67.909 | $21.46 | 216.44% |
| 2022-08-31 | 12 | $105 | $39 | $66.9 | $21.46 | 211.74% |
| 2022-10-25 | 13 | $105 | $39 | $66.9 | $21.46 | 211.74% |
| 2022-11-04 | 13 | $105 | $38 | $62.25 | $21.46 | 190.07% |
| 2022-11-07 | 13 | $105 | $38 | $62.083 | $21.46 | 189.3% |
| 2022-11-10 | 13 | $105 | $38 | $63.545 | $21.46 | 196.11% |
| 2022-12-05 | 14 | $105 | $38 | $61.5 | $21.46 | 186.58% |
| 2022-12-13 | 14 | $105 | $36 | $61.083 | $21.46 | 184.64% |
| 2023-01-09 | 13 | $105 | $36 | $60.916 | $21.46 | 183.86% |
| 2023-01-27 | 15 | $105 | $36 | $61.333 | $21.46 | 185.8% |
| 2023-02-08 | 15 | $105 | $36 | $60.461 | $21.46 | 181.74% |
| 2023-02-28 | 16 | $105 | $36 | $60.461 | $21.46 | 181.74% |
| 2023-03-02 | 16 | $105 | $36 | $57.785 | $21.46 | 169.27% |
| 2023-04-20 | 16 | $105 | $32 | $57.571 | $21.46 | 168.27% |
| 2023-04-26 | 16 | $105 | $32 | $57.428 | $21.46 | 167.6% |
| 2023-05-09 | 16 | $105 | $30 | $56.769 | $21.46 | 164.53% |
| 2023-05-11 | 16 | $105 | $30 | $57.214 | $21.46 | 166.61% |
| 2023-06-06 | 15 | $105 | $30 | $55.307 | $21.46 | 157.72% |
| 2023-06-20 | 14 | $105 | $30 | $54.5 | $21.46 | 153.96% |
| 2023-07-23 | 13 | $105 | $30 | $55.909 | $21.46 | 160.53% |
| 2023-08-09 | 13 | $105 | $26 | $55 | $21.46 | 156.29% |
| 2023-08-31 | 13 | $105 | $26 | $54 | $21.46 | 151.63% |
| 2023-10-08 | 14 | $105 | $26 | $52.666 | $21.46 | 145.41% |
| 2023-11-09 | 13 | $105 | $26 | $48.363 | $21.46 | 125.36% |
| 2023-11-13 | 13 | $105 | $26 | $47.727 | $21.46 | 122.4% |
| 2023-11-20 | 16 | $105 | $26 | $48.571 | $21.46 | 126.33% |
| 2023-12-19 | 16 | $105 | $26 | $47.285 | $21.46 | 120.34% |
| 2023-12-22 | 16 | $105 | $26 | $46.571 | $21.46 | 117.01% |
The Trend in the Analyst Price Target
Over the past 43 months, DNLI's average price target has gone up $17.21.
DNLI reports an average of 115.66% for its upside potential over the past 50 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-27 | 14 | 105 | 36 | 61.333 | 31.47 | 94.89% |
| 2023-05-11 | 16 | 105 | 30 | 57.214 | 27.69 | 106.62% |
| 2023-06-06 | 15 | 105 | 30 | 54.500 | 30.58 | 78.22% |
| 2023-08-14 | 13 | 105 | 26 | 54.000 | 24.43 | 121.04% |
| 2023-09-06 | 14 | 105 | 26 | 52.666 | 24.70 | 113.22% |
DNLI Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.25 | 14 | 0 | 2 | 0 | 0 | 16 |
The Trend in the Broker Recommendations
Over the past 26 months, DNLI's average broker recommendation rating improved by 0.75.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In the context of all US stocks, DENALI THERAPEUTICS INC's variance in analysts' estimates is lower than -4927.83% of them.
- In the context of all US stocks, DENALI THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is greater than 4956.84% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, DENALI THERAPEUTICS INC's number of analysts covering the stock is greater than 4652.47% of them.
- DNLI has a higher average analyst price target than 4281.41% of Pharmaceutical Products stocks.
In the Pharmaceutical Products industry, ARGX, CRSP, and NVAX are the three stocks most similar to DENALI THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Make investment decisions regarding DNLI using the data that counts. Try POWR Ratings for free.